» Articles » PMID: 17161728

Clinical Presentation and Pre-mortem Diagnosis of Variant Creutzfeldt-Jakob Disease Associated with Blood Transfusion: a Case Report

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 2006 Dec 13
PMID 17161728
Citations 116
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Concerns have been raised that variant Creutzfeldt-Jakob disease (vCJD) might be transmissible by blood transfusion. Two cases of prion infection in a group of known recipients of transfusion from donors who subsequently developed vCJD were identified post-mortem and reported in 2004. Another patient from this at-risk group developed neurological signs and was referred to the National Prion Clinic.

Methods: The patient was admitted for investigation and details of blood transfusion history were obtained from the National Blood Service and Health Protection Agency; after diagnosis of vCJD, the patient was enrolled into the MRC PRION-1 trial. When the patient died, brain and tonsil tissue were obtained at autopsy and assessed for the presence of disease-related PrP by immunoblotting and immunohistochemistry.

Findings: A clinical diagnosis of probable vCJD was made; tonsil biopsy was not done. The patient received experimental therapy with quinacrine, but deteriorated and died after a clinical course typical of vCJD. Autopsy confirmed the diagnosis and showed prion infection of the tonsils.

Interpretation: This case of transfusion-associated vCJD infection, identified ante-mortem, is the third instance from a group of 23 known recipients who survived at least 5 years after receiving a transfusion from donors who subsequently developed vCJD. The risk to the remaining recipients of such transfusions is probably high, and these patients should be offered specialist follow-up and investigation. Tonsil biopsy will allow early and pre-symptomatic diagnosis in other iatrogenically exposed individuals at high risk, as in those with primary infection with bovine spongiform encephalopathy prions.

Citing Articles

Human prion diseases and the prion protein - what is the current state of knowledge?.

Nafe R, Arendt C, Hattingen E Transl Neurosci. 2023; 14(1):20220315.

PMID: 37854584 PMC: 10579786. DOI: 10.1515/tnsci-2022-0315.


Enhanced Creutzfeldt-Jakob disease surveillance in the older population: Assessment of a protocol for screening brain tissue donations for prion disease.

Peden A, Libori A, Ritchie D, Yull H, Smith C, Kanguru L Brain Pathol. 2023; 34(2):e13214.

PMID: 37771100 PMC: 10901620. DOI: 10.1111/bpa.13214.


Expression of the cellular prion protein by mast cells in the human carotid body.

Sweetland G, Eggleston C, Bartz J, Mathiason C, Kincaid A Prion. 2023; 17(1):67-74.

PMID: 36943020 PMC: 10038025. DOI: 10.1080/19336896.2023.2193128.


PMCA for ultrasensitive detection of prions and to study disease biology.

Wang F, Pritzkow S, Soto C Cell Tissue Res. 2022; 392(1):307-321.

PMID: 36567368 PMC: 9790818. DOI: 10.1007/s00441-022-03727-5.


Risk of variant Creutzfeldt-Jakob disease transmission by blood transfusion in Australia.

McManus H, Seed C, Hoad V, Kiely P, Kaldor J, Styles C Vox Sang. 2022; 117(8):1016-1026.

PMID: 35609012 PMC: 9544957. DOI: 10.1111/vox.13290.